CN112824391B - Gatifloxacin propenone derivative and preparation method and application thereof - Google Patents

Gatifloxacin propenone derivative and preparation method and application thereof Download PDF

Info

Publication number
CN112824391B
CN112824391B CN201911139923.4A CN201911139923A CN112824391B CN 112824391 B CN112824391 B CN 112824391B CN 201911139923 A CN201911139923 A CN 201911139923A CN 112824391 B CN112824391 B CN 112824391B
Authority
CN
China
Prior art keywords
gatifloxacin
formula
propenone
cyclopropyl
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911139923.4A
Other languages
Chinese (zh)
Other versions
CN112824391A (en
Inventor
方东
胡国强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan University
Original Assignee
Henan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan University filed Critical Henan University
Priority to CN201911139923.4A priority Critical patent/CN112824391B/en
Publication of CN112824391A publication Critical patent/CN112824391A/en
Application granted granted Critical
Publication of CN112824391B publication Critical patent/CN112824391B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention discloses a gatifloxacin propenone derivative, a preparation method and application thereof, wherein the derivative adopts a chemical structural general formula shown in the following formula I:

Description

Gatifloxacin propenone derivative and preparation method and application thereof
Technical Field
The invention belongs to the technical field of innovative drug synthesis, and particularly relates to a gatifloxacin propenone derivative, and a preparation method and application thereof in antitumor drugs.
Background
New drug innovations stem from the discovery of leads, and rational drug molecular design based on structure or mechanism is an effective method of discovering leads. Among pharmacophores with various structures, the propenone structure is not only the characteristic structure of chalcone compounds which are natural active ingredients, but also the characteristic pharmacophore of targeted antitumor drug sunitinib. Therefore, compounds having various pharmacological activities constructed using propenone as a structural fragment are attracting attention. However, most of natural chalcone compounds are polyhydroxy benzene ring substituted propenone compounds, and the bioavailability is low due to poor water solubility, so that clinical application is limited. In addition, the topoisomerase which is an important action target of the anti-tumor drug is combined with the action target of the anti-bacterial fluoroquinolone drug, so that the anti-bacterial activity of the fluoroquinolone drug can be converted into the anti-tumor activity, and the fluoroquinolone C-3 carboxyl is found to be not a pharmacophore necessary for the anti-tumor activity and can be replaced by a bioelectron isostere to improve the anti-tumor activity of the fluoroquinolone C-3 carboxyl. However, no studies have been reported on the substitution of the fluoroquinolone C-3 carboxyl group with aryl propenone. Based on the above, in order to improve the water solubility of chalcones, hydrophilic piperazinyl is introduced to increase the water solubility and improve the bioavailability and the bioactivity of the chalcones, and the invention designs a fluoroquinolone "chalcone-like" derivative with a novel structure by using a dominant pharmacophore "1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one" skeleton of the fluoroquinolone drug gatifloxacin as a substituent of an aryl acrylic ketone structure.
Therefore, the invention aims to provide the gatifloxacin propenone derivative which has an anti-tumor effect and efficacy and a preparation method of the gatifloxacin propenone derivative.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: an propenone derivative of gatifloxacin has a chemical structural formula shown in a general formula I:
ar in the formula I is benzene ring or substituted benzene ring or furan ring or pyridine ring, and the compound is a compound with the following specific structure:
or (b)
The invention relates to a preparation method of an propenone derivative of gatifloxacin, which is prepared from gatifloxacin shown in a formula II as a raw material in a commercial way;
the preparation method comprises the following specific steps:
1) The gatifloxacin imidazole amide compound shown in the formula III is prepared by reacting gatifloxacin shown in the formula II as a raw material with Carbonyl Diimidazole (CDI), and the specific preparation method is as follows:
20g (55.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-carboxylic acid II is taken and dissolved in 500mL of anhydrous acetonitrile, 15.2g (94.0 mmol) of carbonyldiimidazole is added, and the mixture is stirred in a water bath to reflux until the starting material II disappears. Standing at room temperature, filtering and collecting the generated solid, and recrystallizing with acetone to obtain pale yellow crystal of formula III, with yield of 72.6%, m.p.232-234 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.23 to 1.45 (7H, m, cyclopropyl-H and CH) 3 ) 2.78 to 3.56 (8H, m, piperazine-H), 3.87 (s, 3H, OCH) 3 ) 4.46 (1H, m, cyclopropyl-H), 6.72-7.36 (2H, m, imidazole-H), 8.17 (1H, d, 5-H), 8.38 (1H, s, imidazole-H), 8.95 (1H, s, 2-H); MS (m/z): 426[ M+H ]] + Calculation (C) 22 H 24 FN 5 O 3 )：425.47。
As a further improvement, the molar ratio of gatifloxacin shown in the formula II to carbonyl diimidazole is 1:1.0-2.0, and the solvent can be at least one of acetonitrile, tetrahydrofuran, dioxane and dimethylformamide or a mixed solvent of the two solvents.
2) The C-3 formylacetic acid ethyl ester compound of gatifloxacin shown in formula IV is prepared by condensation reaction of gatifloxacin imidazole amide shown in formula III and monoethyl malonate potassium salt under the catalysis of triethylamine-magnesium chloride, and the specific preparation method is as follows:
taking 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3- (1H-imidazole-1-formyl) 17.0g (39.0 mmol) of 8-methoxy-quinolin-4 (1H) -one III, 6.6g (69.1 mmol) of magnesium chloride and 8.3g (49.0 mmol) of potassium monoethyl malonate are added successively to 600mL of anhydrous acetonitrile, 12.5g (12.4 mmol) of triethylamine is added dropwise with stirring in an ice bath, and the mixture is stirred in a water bath and refluxed until the material III disappears. The solvent was distilled off under reduced pressure, 500mL of water was added, the mixture was extracted with methylene chloride (3X 150 mL), the organic phase was combined, washed with water (3X 200 mL), washed with saturated brine (2X 150 mL), and dried over anhydrous sodium sulfate. Recovering dichloromethane at normal pressure, recrystallizing the residue with absolute ethyl alcohol to obtain an off-white crystal compound in the formula IV, wherein the yield is 72.4%, and m.p.215-217 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.23 to 1.57 (10H, m, cyclopropyl-H and 2 XCH) 3 ) 2.77-3.58 (8H, m, piperazine-H), 3.85 (s, 3H, OCH) 3 ),4.11(2H，s，COCH 2 CO), 4.46 (1H, m, cyclopropyl-H), 4.16 (2H, q, CO 2 CH 2 )，8.12(1H，d，5-H)，8.87(1H，s,2-H)；MS(m/z)：446[M+H] + Calculation (C) 23 H 28 FN 3 O 5 ): 445.50. 3) The C-3 formylacetic acid ethyl ester compound of gatifloxacin shown in formula IV is subjected to hydrolysis decarboxylation reaction by using a sodium hydroxide aqueous solution with the mass fraction of 6%, so that the C-3 ethanone compound of gatifloxacin shown in formula V can be conveniently prepared, and the specific preparation method is as follows:
10g (22.5 mmol) of ethyl 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-formylacetate of formula IV is suspended in 200mL of 6% strength by mass aqueous sodium hydroxide solution, and the mixture is stirred in an oil bath to reflux until the disappearance of starting material IV. Standing at room temperature, filtering and collecting the generated solid, washing with water to be neutral, drying, and recrystallizing with absolute ethanol to obtain a pale yellow crystal compound of formula V, wherein the yield is 76.4%, and the m.p. is 225-227 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.23 to 1.55 (7H, m, cyclopropyl-H and CH) 3 ) 2.78 to 3.55 (8H, m, piperazine-H), 3.88 (s, 3H, OCH) 3 ) 4.47 (2H, m, cyclopropyl-H), 8.10 (1H, d, 5-H), 8.86 (1)H，s,2-H)；MS(m/z)：374[M+H] + Calculation (C) 20 H 24 FN 3 O 3 )：373.43。
4) C-3 ethanone of gatifloxacin shown in formula V and aromatic aldehyde are subjected to Claisen-Schmidt aldol condensation reaction in absolute ethyl alcohol under the catalysis of alkali, and after the reaction is completed, the target compound shown in formula I is obtained through treatment, wherein the specific process is as follows:
wherein Ar in the formula I is benzene ring or substituted benzene ring or furan ring or pyridine ring.
The general synthetic preparation operation steps of the target compound shown in the formula I are as follows: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and aromatic aldehyde (3.2 mmol) and base catalyst piperidine (0.1 mL) were added. The mixed reactants are subjected to reflux reaction for 15-24 h, and are placed at room temperature, the generated solid is filtered and collected, and absolute ethyl alcohol is recrystallized, so that a pale yellow crystal of the formula I is obtained.
As a further improvement, the mole ratio of the gatifloxacin C-3 ethanone and the aromatic aldehyde shown in the formula V is 1:1.0-1.5.
The base catalyst is at least one of piperidine, pyridine, triethylamine, morpholine, potassium acetate, sodium hydroxide ethanol solution or potassium hydroxide ethanol solution.
The application of the gatifloxacin propenone derivative in preparing the anti-tumor medicament.
The antitumor drug is used for treating human non-small cell lung cancer, renal cancer, liver cancer, gastric cancer, pancreatic cancer or leukemia.
The gatifloxacin propenone derivative is designed and synthesized by effectively combining a fluoroquinolone skeleton and an aryl propenone pharmacophore based on the principle of amalgamation of pharmacophores, and complementation and activity superposition of pharmacophores with different structures are realized, so that the effects of synergism, toxicity reduction and drug resistance are achieved, and the gatifloxacin propenone derivative can be developed as an antitumor drug with a brand new structure.
Detailed Description
Example 1
1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3-cinnamoyl-8-methoxyquinolin-4 (1H) -one (I-1) having the formula:
that is, ar in formula I is phenyl.
The preparation method of the compound comprises the following steps: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and 0.40g (3.8 mmol) of benzaldehyde and base catalyst piperidine (0.1 mL) were added. The mixed reactants are subjected to reflux reaction for 18 hours, the mixture is placed at room temperature, the generated solid is filtered and collected, and the absolute ethyl alcohol is recrystallized to obtain a pale yellow crystal compound of the formula I-1, the yield is 70.6%, and the m.p.225-227 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.23 to 1.54 (7H, m, cyclopropyl-H and CH) 3 ) 2.78 to 3.62 (8H, m, piperazine-H), 3.87 (s, 3H, OCH) 3 ) 4.45 (1H, m, cyclopropyl-H), 7.42-7.88 (6H, m, ph-H and 2 '-H), 8.14 (1H, d, 5-H), 8.65 (1H, d,3' -H), 8.89 (1H, s, 2-H); MS (m/z): 462[ M+H ]] + Calculation (C) 27 H 28 FN 3 O 3 )：461.54。
Example 2
1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3- (4-methoxycinnamoyl) -8-methoxyquinolin-4 (1H) -one (I-2) having the formula:
that is, ar in formula I is p-methoxyphenyl.
The preparation method of the compound comprises the following steps: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol and 4-methyl was added0.57g (4.2 mmol) of oxybenzaldehyde and 0.1mL of piperidine as a base catalyst. The mixed reactants are subjected to reflux reaction for 20 hours, the mixture is placed at room temperature, the generated solid is filtered and collected, and the absolute ethyl alcohol is recrystallized to obtain a pale yellow crystal of the formula I-2, the yield is 70.4%, and the m.p.228-230 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.23 to 1.56 (7H, m, cyclopropyl-H and CH) 3 ) 2.83 to 3.62 (8H, m, piperazine-H), 3.87,3.90 (6H, 2s,2 XOCH) 3 ) 4.48 (1H, m, cyclopropyl-H), 7.45-8.05 (5H, m, ph-H and 2 '-H), 8.26 (1H, d, 5-H), 8.61 (1H, d,3' -H), 8.88 (1H, s, 2-H); MS (m/z): 492[ M+H ]] + Calculation (C) 28 H 30 FN 3 O 4 )：491.57。
Example 3
1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3- (3, 4-dioxomethylenecinnamoyl) -8-methoxyquinolin-4 (1H) -one (I-3) having the formula:
that is, ar in formula I is 3,4- (dioxymethylene) phenyl.
The preparation method of the compound comprises the following steps: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and 0.53g (3.5 mmol) of 3, 4-dioxomethylenebenzaldehyde and base catalyst piperidine (0.1 mL) were added. The mixed reactants are subjected to reflux reaction for 20 hours, the mixture is placed at room temperature, the generated solid is filtered and collected, and absolute ethyl alcohol is recrystallized to obtain a pale yellow crystal of the formula I-3, the yield is 75.2%, and the m.p.234-236 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.24 to 1.57 (7H, m, cyclopropyl-H and CH) 3 ) 2.76-3.63 (8H, m, piperazine-H), 3.88 (3H, s, OCH) 3 ) 4.47 (1H, m, cyclopropyl-H), 6.22 (2H, s, OCH) 2 O), 7.46 to 7.94 (4H, m, ph-H and 2 '-H), 8.27 (1H, d, 5-H), 8.65 (1H, d,3' -H), 8.87 (1H, s, 2-H); MS (m/z): 506[ M+H ]] + Calculation (C) 28 H 28 FN 3 O 5 )：505.55。
Example 4
1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3- (3, 4, 5-trimethoxycinnamoyl) -8-methoxyquinolin-4 (1H) -one (I-4) having the formula:
that is, ar in the formula I is 3,4, 5-trimethoxyphenyl.
The preparation method of the compound comprises the following steps: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and 0.63g (3.2 mmol) of 3,4, 5-trioxybenzaldehyde and base catalyst piperidine (0.1 mL) were added. The mixed reactants are subjected to reflux reaction for 20 hours, the mixture is placed at room temperature, the generated solid is filtered and collected, and the absolute ethyl alcohol is recrystallized to obtain a pale yellow crystal of the formula I-4, the yield is 61.4%, and the m.p.225-227 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.22 to 1.56 (7H, m, cyclopropyl-H and CH) 3 ) 2.77-3.58 (8H, m, piperazine-H), 3.87,3.90,3.93 (12H, 3s,4 XOCH) 3 ) 4.57 (1H, m, cyclopropyl-H), 7.46 to 7.87 (3H, m, ph-H and 2 '-H), 8.23 (1H, d, 5-H), 8.64 (1H, d,3' -H), 8.87 (1H, s, 2-H); MS (m/z): 552[ M+H ]] + Calculation (C) 30 H 34 FN 3 O 6 )：551.62。
Example 5
1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3- (4-methylcinnamoyl) -8-methoxyquinolin-4 (1H) -one (I-5) having the formula:
that is, ar in formula I is p-methyl-phenyl.
The preparation method of the compound comprises the following steps: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and 0.58g (4.8 mmol) of 4-methylbenzaldehyde and the base catalyst piperidine were added0.1 mL). The mixed reactants are subjected to reflux reaction for 15 hours, the mixture is placed at room temperature, the generated solid is filtered and collected, and absolute ethyl alcohol is recrystallized to obtain a pale yellow crystal of the formula I-5, the yield is 60.7%, and the m.p.212-214 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.21 to 1.55 (7H, m, cyclopropyl-H and CH) 3 )，2.26(3H，s，Ph-CH 3 ) 2.76 to 3.58 (8H, m, piperazine-H), 3.87 (3H, s, OCH) 3 ) 4.56 (1H, m, cyclopropyl-H), 7.46-7.87 (5H, m, ph-H and 2 '-H), 8.24 (1H, d, 5-H), 8.58 (1H, d,3' -H), 8.86 (1H, s, 2-H); MS (m/z): 476[ M+H ]] + Calculation (C) 28 H 30 FN 3 O 3 )：475.57。
Example 6
1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3- (4-fluorocinnamoyl) -8-methoxyquinolin-4 (1H) -one (I-6) having the formula:
that is, ar in formula I is p-fluoro-phenyl.
The preparation method of the compound comprises the following steps: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and 0.48g (3.8 mmol) of 4-fluorobenzaldehyde and piperidine as a base catalyst (0.1 mL) were added. The mixed reactants are subjected to reflux reaction for 16 hours, the mixture is placed at room temperature, the generated solid is filtered and collected, and the absolute ethyl alcohol is recrystallized to obtain a pale yellow crystal of the formula I-6, the yield is 72.6%, and the m.p.214-216 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.25 to 1.62 (7H, m, cyclopropyl-H and CH) 3 ) 2.83 to 3.67 (8H, m, piperazine-H), 3.89 (3H, s, OCH) 3 ) 4.62 (1H, m, cyclopropyl-H), 7.52-8.14 (5H, m, ph-H and 2 '-H), 8.32 (1H, d, 5-H), 8.65 (1H, d,3' -H), 9.07 (1H, s, 2-H); MS (m/z): 480[ M+H ]] + Calculation (C) 27 H 27 F 2 N 3 O 3 )：479.53。
Example 7
1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3- (4-chlorocinnamoyl) -8-methoxyquinolin-4 (1H) -one (I-7) having the formula:
that is, ar in formula I is p-chlorophenyl.
The preparation method of the compound comprises the following steps: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and 0.45g (3.2 mmol) of 4-chlorobenzaldehyde and piperidine as a base catalyst (0.1 mL) were added. The mixed reactants are subjected to reflux reaction for 20 hours, the mixture is placed at room temperature, the generated solid is filtered and collected, and the absolute ethyl alcohol is recrystallized to obtain a pale yellow crystal of the formula I-7, the yield is 58.5%, and the m.p.215-217 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.25 to 1.60 (7H, m, cyclopropyl-H and CH) 3 ) 2.81 to 3.60 (8H, m, piperazine-H), 3.88 (3H, s, OCH) 3 ) 4.58 (1H, m, cyclopropyl-H), 7.52-8.06 (5H, m, ph-H and 2 '-H), 8.27 (1H, d, 5-H), 8.60 (1H, d,3' -H), 9.05 (1H, s, 2-H); MS (m/z): 496[ M+H ]] + ( 35 Cl), calculation (C 27 H 27 FClN 3 O 3 )：495.99。
Example 8
1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3- (4-bromocinnamoyl) -8-methoxyquinolin-4 (1H) -one (I-8) having the formula:
that is, ar in formula I is p-bromophenyl.
The preparation method of the compound comprises the following steps: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and 0.67g (3.6 mmol) of 4-bromobenzaldehyde and the base catalyst piperidine (0.1 mL) were added. Reflux reaction of the mixed reactants for 20h, standing at room temperature, filtering and collecting the generated solid, recrystallizing with absolute ethanol to obtain yellowish crystal of formula I-8, and obtainingThe rate is 65.8%, m.p.224-226 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.25 to 1.57 (7H, m, cyclopropyl-H and CH) 3 ) 2.87-3.60 (8H, m, piperazine-H), 3.92 (3H, s, OCH) 3 ) 4.58 (1H, m, cyclopropyl-H), 7.53 to 8.03 (5H, m, ph-H and 2 '-H), 8.28 (1H, d, 5-H), 8.62 (1H, d,3' -H), 9.02 (1H, s, 2-H); MS (m/z): 540 and 542[ M+H ]] + ( 79 Br and 81 br), calculation (C 27 H 27 FBrN 3 O 3 )：540.44。
Example 9
1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3- (4-nitrocinnamoyl) -8-methoxyquinolin-4 (1H) -one (I-9) having the formula:
that is, ar in formula I is p-nitrophenyl.
The preparation method of the compound comprises the following steps: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and 0.54g (3.6 mmol) of 4-nitrobenzaldehyde and piperidine as a base catalyst (0.1 mL) were added. The mixed reactants are subjected to reflux reaction for 24 hours, the mixture is placed at room temperature, the generated solid is filtered and collected, and absolute ethyl alcohol is recrystallized to obtain yellow crystals of the formula I-9, the yield is 76.4%, and the m.p.241-243 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.26 to 1.62 (7H, m, cyclopropyl-H and CH) 3 ) 3.02-3.65 (8H, m, piperazine-H), 3.95 (3H, s, OCH) 3 ) 4.67 (1H, m, cyclopropyl-H), 7.53 to 8.16 (5H, m, ph-H and 2 '-H), 8.42 (1H, d, 5-H), 8.68 (1H, d,3' -H), 9.16 (1H, s, 2-H); MS (m/z): 507, calculate (C 27 H 27 FN 4 O 5 )：506.54。
Example 10
1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3- (4-hydroxy-cinnamoyl) -8-methoxyquinolin-4 (1H) -one (I-10) having the formula:
that is, ar in formula I is 4-hydroxy-phenyl.
The preparation method of the compound comprises the following steps: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and 0.49g (4.0 mmol) of 4-hydroxy-benzaldehyde and the base catalyst piperidine (0.1 mL) were added. The mixed reactants are subjected to reflux reaction for 22 hours, the mixture is placed at room temperature, the generated solid is filtered and collected, and absolute ethyl alcohol is recrystallized to obtain yellow crystals of the formula I-10, the yield is 52.6%, and the m.p.223-225 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.21 to 1.56 (7H, m, cyclopropyl-H and CH) 3 ) 2.75 to 3.57 (8H, m, piperazine-H), 3.87 (3H, s, OCH) 3 ) 4.54 (1H, m, cyclopropyl-H), 7.45 to 7.86 (5H, m, ph-H and 2 '-H), 8.16 (1H, d, 5-H), 8.57 (1H, d,3' -H), 8.88 (1H, s, 2-H), 10.54 (1H, s, OH); MS (m/z): 478, calculate (C) 27 H 28 FN 3 O 4 )：477.54。
Example 11
1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3- [3- (pyridin-3-yl) acryloyl ] -8-methoxyquinolin-4 (1H) -one (I-11) having the formula:
that is, ar in formula I is 3-pyridyl.
The preparation method of the compound comprises the following steps: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and 0.37g (3.6 mmol) of 3-pyridineal and piperidine as a base catalyst (0.1 mL) were added. The mixed reactants are subjected to reflux reaction for 15 hours, the mixture is placed at room temperature, the generated solid is filtered and collected, and absolute ethyl alcohol is recrystallized to obtain yellow crystals of the formula I-11, the yield is 76.4%, and the m.p.241-243 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.25 to 1.64 (7H, m, cyclopropyl-H and CH) 3 ) 3.11 to 3.75 (8H, m, piperacillin)oxazine-H), 3.92 (3H, s, OCH) 3 ) 4.65 (1H, m, cyclopropyl-H), 7.52 (1H, d,2 '-H), 8.28-9.06 (5H, 5-H, 3' -H and pyridine-H), 9.18 (1H, s, 2-H); MS (m/z): 463, calculate (C 26 H 27 FN 4 O 3 )：462.53。
Example 12
1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -3- [3- (furan-2-yl) acryloyl ] -8-methoxyquinolin-4 (1H) -one (I-12) having the formula:
that is, ar in formula I is 2-furyl.
The preparation method of the compound comprises the following steps: the preparation method of the compound comprises the following steps: 1.1g (3.0 mmol) of 1-cyclopropyl-6-fluoro-7- (3-methylpiperazin-1-yl) -8-methoxy-quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of absolute ethanol, and 0.38g (4.0 mmol) of 2-furaldehyde and 0.1mL of piperidine as a base catalyst were added. The mixed reactants are subjected to reflux reaction for 20 hours, the mixture is placed at room temperature, the generated solid is filtered and collected, and absolute ethyl alcohol is recrystallized to obtain yellow crystals of the formula I-12, the yield is 62.6%, and the m.p.235-237 ℃. 1 H NMR(400MHz,CD 3 Cl) δ:1.26 to 1.58 (7H, m, cyclopropyl-H and CH) 3 ) 2.86 to 3.63 (8H, m, piperazine-H), 3.90 (3H, s, OCH) 3 )，4.64(2H，q，N-CH 2 ) 6.95 to 7.87 (4H, m,2'-H and furan-H), 8.28 (1H, d, 5-H), 8.61 (1H, d,3' -H), 8.96 (1H, s, 2-H); MS (m/z): 452[ M+H ]] + Calculation (C) 25 H 26 FN 3 O 4 )：451.50。
Test examples
1. In vitro antitumor Activity assay of Gatifloxacin's propenone derivative provided in examples 1-12
1. Sample for sample
Taking the propenone derivative of gatifloxacin and the 10-Hydroxycamptothecin (HC) of classical antineoplastic TOPO inhibitor, chalcone tyrosinase inhibitor Sunitinib (SN), broad-spectrum anticancer drug Doxorubicin (DOX) and the parent compound Gatifloxacin (GF) provided in examples 1-12 as test samples, 15 total, wherein HC, SN and GF are control experiment groups, and the samples in examples 1-12 are test experiment groups;
thiazole blue (MTT), HC, SN, GF are all manufactured by Sigma company; the RPMI-1640 culture solution is manufactured by GIBCO company; the other reagents used are all domestic analytically pure reagents.
The experimental cancer cell lines are respectively a human non-small cell lung cancer cell line A549, a human kidney cancer cell line 769-P, a human liver cancer cell line Hep-3B, a human gastric cancer cell line HGC27, a human pancreatic cancer cell line Panc-1 and a human leukemia cell line HL60, which are all purchased from Shanghai cell banks of China academy of sciences. Human-derived renal clear cell carcinoma cell sunitinib resistant strain 7SuR was purchased from Shanghai ze leaf biotechnology limited, while normal cells were obtained from african green monkey kidney cell strain VERO, and purchased from Shanghai general derivative technology limited.
2. Measurement method
The measuring method comprises the following specific steps:
1) Firstly, the 15 samples were dissolved in dimethyl sulfoxide (DMSO) to prepare 1.0X10 s - 4 mol·L -1 Stock solution of concentration, which was then diluted with 10% by mass of RPMI-1640 medium of calf serum to 5 concentration gradients (0.1, 1.0, 5.0, 10.0, 50.0. Mu. Mol.L) -1 ) Is a working fluid of (2);
2) Taking a non-small cell lung cancer cell strain A549, a human kidney cancer cell strain 769-P, a human liver cancer cell strain Hep-3B, a human gastric cancer cell strain HGC27, a human pancreatic cancer cell strain Panc-1, a human leukemia cell strain HL60, a human-derived renal clear cell carcinoma cell sunitinib drug-resistant strain 7SuR and an African green monkey kidney cell strain VERO in logarithmic phase, inoculating 6000 cells in each well into a 96-well plate, then respectively adding working solutions with 5 concentration gradients of the 15 samples into each well, and adding 5 g.L into each well after 48 hours –1 10. Mu.L of MTT (thiazole blue) solution was further cultured for 4 hours, and then 100. Mu.L of 10% strength by mass Sodium Dodecyl Sulfate (SDS) solution was added. Culturing for 24 hours, and then measuring the absorbance (OD) value at 570nm wavelength by using an enzyme-labeled instrument;
3) The inhibition rate of the samples for the samples with different concentrations on cancer cells is calculated according to the following formula:
cancer cell inhibition ratio = [ (1-experimental group OD value)/control group OD value ] ×100%;
then, carrying out linear regression on the cancer cell inhibition rate corresponding to each concentration by using the logarithmic value of each concentration of the sample to obtain a dose-effect equation, and calculating the half inhibition concentration (IC 50) of the sample to the experimental cancer cells from the obtained dose-effect equation; each data was measured in triplicate and averaged, and the results are shown in table 1.
Table 1 anti-tumor Activity (IC) of each sample 50 )
As can be seen from Table 1, the compounds provided in examples 1-12 have significantly stronger inhibitory activity against 7 cancer cells than the parent compound gatifloxacin, especially a portion of the compounds have stronger growth inhibitory activity against human non-small cell lung cancer cell line A549 than the control Hydroxycamptothecin (HC), tyrosine kinase inhibitors Sunitinib (SN) and Doxorubicin (DOX), IC 50 The value reaches or approaches nanomolar concentration, and has the value of developing new medicines. More significantly, the compounds provided in examples 1-12 also showed extremely strong sensitivity to sunitinib resistant strain 7SuR, showed strong resistance to drugs, and also showed low toxicity to normal cells VERO, with the property of drug formation. Therefore, according to the general approach of drug development, conventional antitumor in-vitro screening is carried out first, and then targeted research is carried out, so that the compound has strong antitumor activity, drug resistance activity and lower cytotoxicity, and can be prepared into antitumor drugs by salifying with acid acceptable to human bodies or mixing with a medicinal carrier.

Claims (4)

1. An propenone derivative of gatifloxacin characterized by being a typical compound of the structure:
2. the method for preparing the propenone derivative of gatifloxacin of claim 1 comprising the specific steps of:
1) Taking gatifloxacin shown in a formula II as a raw material, reacting with Carbonyl Diimidazole (CDI) to prepare a gatifloxacin imidazole amide compound shown in a formula III, and then carrying out condensation reaction with monoethyl malonate potassium salt to prepare a C-3 formylacetic acid ethyl ester compound of gatifloxacin shown in a formula IV; finally, the gatifloxacin C-3 ethanone shown in the formula V is prepared through hydrolysis decarboxylation reaction in the formula IV:
2) The gatifloxacin C-3 ethanone and aromatic aldehyde shown in the formula V undergo a Claisen-Schmidt condensation reaction under the catalysis of alkali to form a propenone structure, and the propenone derivative of the gatifloxacin shown in the claim 1 can be prepared through post-treatment;
the molar ratio of gatifloxacin shown in the formula II to CDI is 1:1.0-2.0, the molar ratio of gatifloxacin imidazole amide shown in the formula III to monoethyl malonate potassium salt is 1:1.0-1.5, and the molar ratio of gatifloxacin-3 ethanone shown in the formula V to aromatic aldehyde is 1:1.0-2.0.
3. Use of a gatifloxacin propenone derivative of claim 1 in the preparation of an antitumor medicament.
4. The use of a gatifloxacin propenone derivative of claim 3 in the manufacture of an antineoplastic medicament wherein the antineoplastic medicament is a medicament for the treatment of human non-small cell lung cancer, kidney cancer, liver cancer, stomach cancer, pancreatic cancer or leukemia.
CN201911139923.4A 2019-11-20 2019-11-20 Gatifloxacin propenone derivative and preparation method and application thereof Active CN112824391B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911139923.4A CN112824391B (en) 2019-11-20 2019-11-20 Gatifloxacin propenone derivative and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911139923.4A CN112824391B (en) 2019-11-20 2019-11-20 Gatifloxacin propenone derivative and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN112824391A CN112824391A (en) 2021-05-21
CN112824391B true CN112824391B (en) 2023-08-18

Family

ID=75906285

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911139923.4A Active CN112824391B (en) 2019-11-20 2019-11-20 Gatifloxacin propenone derivative and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN112824391B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113896727B (en) * 2021-10-26 2023-05-23 河南大学 Preparation method and application of isofraxine analogue from gatifloxacin to isofraxine analogue
CN113912603B (en) * 2021-10-26 2023-06-02 河南大学 Preparation method and application of isofraxine analogue from ciprofloxacin to isofraxine analogue

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103694242A (en) * 2013-12-10 2014-04-02 中国科学院昆明植物研究所 Pyrazolopyrimidine compound and pharmaceutical composition thereof as well as pharmaceutical application of pyrazolopyrimidine compound
CN106256823A (en) * 2015-06-19 2016-12-28 河南大学 A kind of α of Gatifloxacin, alpha, beta-unsaturated ketone derivant and its preparation method and application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103694242A (en) * 2013-12-10 2014-04-02 中国科学院昆明植物研究所 Pyrazolopyrimidine compound and pharmaceutical composition thereof as well as pharmaceutical application of pyrazolopyrimidine compound
CN106256823A (en) * 2015-06-19 2016-12-28 河南大学 A kind of α of Gatifloxacin, alpha, beta-unsaturated ketone derivant and its preparation method and application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKUO KOSUGE et al..Synthesis and Some Reactions of 6-Bromooxindole.《Chem.Pharm.Bull》.1985,第33卷(第33期),第1415页. *

Also Published As

Publication number Publication date
CN112824391A (en) 2021-05-21

Similar Documents

Publication Publication Date Title
CN106256823A (en) A kind of α of Gatifloxacin, alpha, beta-unsaturated ketone derivant and its preparation method and application
CN111303026A (en) Propenone derivative of enrofloxacin and preparation method and application thereof
CN112824391B (en) Gatifloxacin propenone derivative and preparation method and application thereof
CN106316946B (en) A kind of α of Ciprofloxacin, alpha, beta-unsaturated ketone derivative and its preparation method and application
CN112824415A (en) Ofloxacin acrylketone derivative and preparation method and application thereof
CN111303189A (en) Propenone derivative of rufloxacin, and preparation method and application thereof
CN111646974A (en) N-methyl gatifloxacin propenone derivative and preparation method and application thereof
CN111303190A (en) Propenone derivative for removing N-methylrufloxacin and preparation method and application thereof
CN111303027A (en) Fluroxacin acrylketone derivative and preparation method and application thereof
CN112824396B (en) Acrylic ketone derivative of N-acetyl lomefloxacin and preparation method and application thereof
CN112824397B (en) Lomefloxacin propenone derivative and preparation method and application thereof
CN106279019A (en) A kind of α of enrofloxacin, alpha, beta-unsaturated ketone derivant and its preparation method and application
CN106316948B (en) A kind of α of N- methyl Ciprofloxacin, alpha, beta-unsaturated ketone derivative and its preparation method and application
CN111647004B (en) Propenone derivative for removing N-methylofloxacin and preparation method and application thereof
CN111646975B (en) N-methyl lomefloxacin allyl ketone derivative and preparation method and application thereof
CN111646937B (en) Propenone derivative of N-acetyl ciprofloxacin and preparation method and application thereof
CN112824401B (en) Acrylic ketone derivative of N-acetyl gatifloxacin and preparation method and application thereof
CN112824406B (en) Enoxacin propenone derivative and preparation method and application thereof
CN111393453A (en) Acrylketone derivative of levofloxacin, and preparation method and application thereof
CN112824405B (en) Acrylic ketone derivative of N-methyl enoxacin and preparation method and application thereof
CN112824388B (en) Acrylic ketone derivative of norfloxacin and preparation method and application thereof
CN112824416A (en) Propenone derivative for removing N-methyllevofloxacin, and preparation method and application thereof
CN112824414A (en) Propenone derivative of N-acetylofloxacin and preparation method and application thereof
CN112824389B (en) Acrylic ketone derivative of N-acetylnorfloxacin and preparation method and application thereof
CN112830926B (en) Acrylic ketone derivative of N-acetyl moxifloxacin and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant